An Overview on Antifungal Resistance
DOI:
https://doi.org/10.48047/av2esg11Keywords:
Antifungal resistance; Candida auris; Azole resistance; Aspergillus fumigatus; Echinocandins; Antifungal stewardship; Multidrug resistance.Abstract
Fungal infections account for substantial morbidity and mortality worldwide, especially in immunocompromised populations. While antifungal agents such as azoles, echinocandins, and amphotericin B have improved outcomes, increasing resistance among clinically important species poses major therapeutic challenges. Unlike antibacterial resistance, antifungal resistance develops more slowly but is particularly concerning due to the limited number of antifungal drug classes available. Resistance mechanisms include mutations in drug targets, efflux pump overexpression, biofilm formation, and environmental exposure to antifungal agents, particularly in agriculture. The global rise of resistant pathogens highlights the urgent need for enhanced diagnostics, surveillance, and stewardship strategies.
Downloads
References
Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis 2023;23:405–19.
Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 2020;16:e1008921.
Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol 2022;20:557–71.
Rybak JM, Muñoz JF, Barker KS, Parker JE, Esquivel BD, Berkow EL, et al. Mutations in erg3, erg11, and upc2 contribute to azole resistance in clinical isolates of Candida albicans. mBio 2021;12:e03205-20.
Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing and epidemiology of invasive mycoses: moving beyond Candida and Aspergillus. Clin Microbiol Rev 2022;35:e00007-21.
Denning DW. Antifungal drug resistance: an update. European Journal of Hospital Pharmacy. 2022 Mar;29(2):109-112.
Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018 May 18;360(6390):739-742.
Arastehfar A, Gabaldón T, Garcia-Rubio R. Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium. Antibiotics 2020 Dec 8;9(12) :877.
Hoenigl M, Salmanton-García J, Walsh TJ. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectios Disease. 2021 Aug;21(8):246-257.
Berman J, Krysan DJ. Drug resistance and tolerance in fungi. Natural Review. Microbiology. 2020 Jun;18(6):319-331.
Robbins N, Caplan T, Cowen LE. Molecular evolution of antifungal drug resistance. Annual Revesion of Microbiology. 2017; 71:753–775.
Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Natural Review Microbiology. 2022 Sep;20(9):557-571.
Fang T, Lu H, Jiang Y. Extracellular fungal Hsp90 represents a promising therapeutic target for combating fungal infections. European Journal of Pharmaceutical Sciences.2025 April 1;207 (107041): 0928-0987.
Khalifa HO, Oreiby A, Abdelhamid MAA, Ki M-R, Pack SP. Biomimetic Antifungal Materials: Countering the Challenge of Multidrug-Resistant Fungi. Biomimetics. 2024; 9(7):425.
Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. 2021 May;186(2):289-298.
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes and Metabolic. Syndrome. 2021 Jul-Aug; 15(4):102146.
Verweij PE, Lucas JA, Arendrup MC. The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda. Fungal Biology Reviews.2020;34(4): 202-214.
Chakrabarti A, Sood P, Rudramurthy SM. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Medicine. 2015 Feb ;41(2):285–95.
Perlin DS, Wiederhold NP. Culture-independent molecular methods for detection of antifungal resistance mechanisms and fungal identification. Journal of Infectious Disease. 2017 Aug 15;216(3): 458-465.
Rautemaa-Richardson R, Rautemaa V, Al-Wathiqi F, Moore CB, Craig L, Felton TW, et al. Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital. Journal of Antimicrobial & Chemotherapy. 2018 Dec 1;73(12):3488-3495.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
